<DOC>
	<DOCNO>NCT02047890</DOCNO>
	<brief_summary>This open-label , non-randomized , dose-escalating Phase I study evaluate safety , tolerability , pharmacokinetics BAY1000394 give 3 day / 4 day schedule Japanese subject advanced malignancy .</brief_summary>
	<brief_title>Japanese BAY1000394 Monotherapy Phase I Study</brief_title>
	<detailed_description />
	<criteria>Japanese male female subject age â‰¥20 year Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Life expectancy least 12 week Subjects advance , histologically cytologically confirm solid tumor , amenable standard therapy , standard therapy available , subject must actively refuse treatment would regard standard , judgment investigator , experimental treatment clinically ethically acceptable At least 1 tumor lesion evaluable computer tomography ( CT ) scan magnetic resonance imaging ( MRI ) accord Response Evaluation Criteria Solid Tumors ( RECIST ) version 1.1 Adequate bone marrow , liver , renal function Anticancer chemotherapy immunotherapy within 4 week study entry . Mitomycin C nitrosoureas give within 6 week study entry . Radiotherapy target lesion within 3 week prior first dose study drug . Use biological response modifier , granulocyte colonystimulating factor ( GCSF ) , within 3 week prior first dose study drug . Symptomatic metastatic brain meningeal tumor . Investigational drug treatment outside study within 4 week prior study entry . Blood pressure &lt; 100/60 mmHg pulse &gt; 100 BPM</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>CDK inhibitor</keyword>
	<keyword>BAY1000394</keyword>
	<keyword>Advanced malignancy</keyword>
	<keyword>Japanese</keyword>
</DOC>